The purpose of the pilot study was to evaluate Lumito’s product Scizys, together with the company’s upconverting nanoparticles (UCNPs), in degenerative disease models. Degenerative disease models are used in research to simulate conditions in which tissues and organs progressively deteriorate, such as neurological or muscular diseases.
 
The pilot study demonstrated that Lumito’s technology, compared to current methods, can extract more information from each tissue sample. This provides researchers with a clearer understanding of disease progression, since even small differences in disease markers within the tissue can be crucial, and enables more confident decision-making in the development and evaluation of new drugs.
 

“We are very pleased with the positive results from the pilot study. Moving on to customer samples is an important milestone and paves the way for Truly Labs to offer Scizys testing to their clients. At the same time, we continue to optimise the amount of information can be extracted from each sample, strengthening the value of our technology for both researchers and drug developers,” says Sanna Wallenborg, CEO of Lumito.

“By using Lumito’s UCNP technology, we observe improved sensitivity in our measurements, which is very promising. It enables automated and more precise quantification, reinforcing our current manual and semi-quantitative evaluation methods, and thus allows us to deliver more reliable and consistent results. We are confident that this method will add significant value for our customers,” says Charlott Brunmark, CSO of Truly Labs.

 
This work follows the strategic partnership initiated with Truly Labs in December 2024 and marks the next stage in our collaborative development. The next step is to begin testing with customer samples, in collaboration with Truly Labs, aiming to validate the pilot study results and further enhance the utility of Lumito’s technology in practical research settings.